Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TailorDose-II: Therapeutic dose monitoring of cytostatic drugs for breast cancer
2024-514818-12-00Phase 4Authorised
- Sponsor
- Karolinska Institutet
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin, cyclophosphamide, doxorubicin, paclitaxel accord and docetaxel in breast cancer, sponsored by Karolinska Institutet. Primary endpoint: Incidence of grade 1-2 anemia in high vs low exposure groups (EPI + CPA). Planned start Aug 2024; status: authorised.
02
Drugs
epirubicincyclophosphamidedoxorubicinpaclitaxel accorddocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514818-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514818-12-00.